Oral Solid Dosage Contract Manufacturing Market To Reach $54.7 Billion By 2030

Oral Solid Dosage Contract Manufacturing Market Growth & Trends

The global oral solid dosage contract manufacturing market size is expected to reach USD 54.7 billion by 2030 and expand at a CAGR of 5.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

Oral solids are widely accepted dosage forms in the pharmaceutical sector since they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as control release and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency. Thereby, it is anticipated to propel market growth potential.

Technological advancements in the development and bulk manufacturing of oral solid dosage forms are among the primary factors supporting the fast-track commercialization of these products. Currently, a diverse array of dosage forms is accessible in the market. However, the nutraceutical and pharmaceutical industries consistently put effort into developing OSD forms. This preference is due to their ease of handling, convenient consumption, and positive patient adherence. Anticipated advancements in technology and materials of OSD forms are projected to boost the demand for these formulations.

Furthermore, R&D investments by CMOs and CDMOs contribute to enhanced innovation in manufacturing processes, formulation development, & analytical technologies. This can lead to the adoption of more efficient and advanced manufacturing techniques in the production of oral solid dosage forms. Also, investments in R&D result in the expansion of manufacturing capabilities and improved scalability. This allows CMOs and CDMOs to offer larger volumes of oral solid dosage production to meet the increasing demand from pharmaceutical companies.

Moreover, the industry witnessed many strategic movements in 2023, such as collaborations, partnerships, M&As, service expansion, etc.

• In July 2023, Aenova Group and Galvita entered a strategic partnership to improve the formulation, production, and development of oral dosage forms.

• In April 2023, Aenova invested approximately USD 21.96 million (20 million euros) to expand its high-volume solids site in Tittmoning, resulting in increased capacity.

• In January 2023, Catalent and Ethicann collaborated to develop Ethicann’s clinical drug pipeline using Catalent’s technology known as Orally Disintegrating Tablet (ODT) technology.

 Request a free sample copy or view report summary: Oral Solid Dosage Contract Manufacturing Market Report

Oral Solid Dosage Contract Manufacturing Market Report Highlights

• The tablets segment dominated the market with a revenue share of 32.7% in 2023. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth

• The controlled release segment accounted for the largest share of 52.2% in 2023. This growth is attributed to advancements in oral controlled release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for control release dosage forms is anticipated to boost segmental revenue growth in the near future

• Based on end-use, the large size companies segment accounted for the largest share of 54.8% in 2023. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption

• Asia Pacific led the global market in 2023 and is projected to witness the fastest CAGR of 6.3% during the forecast years. China and India are the powerhouses of oral solid dosage contract manufacturing organizations with significantly lower prices. Further, expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea have been considered major players in the pharmaceutical industry due to their expanding manufacturing capabilities

Oral Solid Dosage Contract Manufacturing Market Segmentation

Grand View Research has segmented the global oral solid dosage contract manufacturing market based on product type, mechanism, service, drug potency, prescription type, therapeutic area, end-use, region:

Oral Solid Dosage Contract Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Tablets

  • Compressed Tablets

  • Orally Disintegrating Tablets (ODT)

  • Chewable Tablets

  • Bi-layer or Tri-layer Tablets

  • Sublingual or Buccal Tablets

  • Others

• Capsules

  • Hard Gelatin Capsules

  • Soft Gelatin Capsules

• Powders

• Granules

• Others

Oral Solid Dosage Contract Manufacturing Mechanism Outlook (Revenue, USD Million, 2018 - 2030)

• Immediate Release

• Delayed Release

• Controlled Release

Oral Solid Dosage Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Product Development

• Fill Finish Product Manufacturing

• API Manufacturing

• Others

Oral Solid Dosage Contract Manufacturing Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)

• High Potent Drugs

• Moderate Potent Drugs

• Low Potent Drugs

Oral Solid Dosage Contract Manufacturing Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription Drugs

• Over-The-Counter Drugs

Oral Solid Dosage Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cardiovascular Diseases

• Metabolic Disorders

• Neurological Disorders

• infectious Diseases

• Gastrointestinal Diseases

• Other Therapeutic Areas

Oral Solid Dosage Contract Manufacturing End-Use Outlook (Revenue, USD Million, 2018 - 2030)

• Large Size Companies

• Medium & Small Size Companies

• Others

Oral Solid Dosage Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Oral Solid Dosage Contract Manufacturing Market

• Catalent, Inc.

• Lonza

• Aenova Group

• Boehringer Ingelheim International GmbH

• Jubilant Pharmova Limited

• Patheon Pharma Services

• Recipharm AB.

• Corden Pharma International

• Siegfried Holding AG

• Piramal Pharma Solutions

• AbbVie Contract Manufacturing

• Next Pharma AB